'Italian cohort of nivolumab Expanded Access Programme (EAP): Preliminary data from a real-world population.'

Authors :: Francesca Sperandi
Paola Antonelli
Diana Giannarelli
Filippo de Marinis
Silvia Quadrini
Paolo Bidoli
Daniele Turci
Milena Vitali
Luana Calabrò
Irene Prediletto
Anna Manzo
Angelo Delmonte
Marcello Tiseo
Lucio Crinò
Gabriele Minuti
Hector Soto Parra
Fabiana Vitiello
Francesco Grossi
Domenico Galetta
Simone Scagnoli
Crinò L, Bidoli P, Delmonte A, Grossi F, De Marinis F, Sperandi F, Vitiello F, Vitali M, Soto Parra HJ, Scagnoli S, Minuti G, Calabrò L, Tiseo M, Turci D, Quadrini S, Antonelli P, Manzo A, Prediletto I, Giannarelli D, Galetta D.
Publication Year :: 2016
Abstract: 3067Background: Nivolumab is the first checkpoint inhibitor approved for the treatment of squamous non small cell lung cancer (Sq-NSCLC) to show a survival benefit in a randomised phase III trial. ...

Tools